Bristol-Myers Squibb and Lonza Expand Manufacturing Agreement
31 October 2014 - 4:00AM
Business Wire
Bristol-Myers Squibb Company (NYSE:BMY) and Lonza today
announced a multi-year expansion of their existing biologics
manufacturing agreement. The contract expansion will include the
production of commercial quantities of a second Bristol-Myers
Squibb biologic medicine at Lonza’s mammalian manufacturing
facility in Portsmouth, New Hampshire. Financial terms were not
disclosed.
Biologic medicines that treat serious diseases are an integral
part of Bristol-Myers Squibb’s specialty care portfolio and R&D
pipeline. Bristol-Myers Squibb and Lonza have been collaborating
since 2003 to produce commercial supplies of a biologics medicine
marketed by Bristol-Myers Squibb worldwide. Currently, Lonza also
produces clinical supplies of an investigational biologics medicine
for Bristol-Myers Squibb.
“Our expanded relationship with Lonza is an important example of
our global manufacturing strategy to meet anticipated demand for
our commercial biologics portfolio and prepare to bring our
late-stage clinical assets to patients by supplementing our
in-house manufacturing capabilities,” said Lou Schmukler,
president, Global Manufacturing & Supply, Bristol-Myers
Squibb.
Lonza’s development and manufacturing facilities offer proven
expression systems and established platform processes for
streamlined scale-up throughout the clinical pipeline. In addition
to its state-of-the-art Portsmouth facility, Lonza offers three
additional clinical-to-commercial mammalian production facilities
in Tuas, Singapore; Porrino, Spain; and Slough, United Kingdom.
"We are pleased to extend our relationship with Bristol-Myers
Squibb for the commercial production of their innovative drug
substance, said Marc Funk, COO of Lonza’s Pharma & Biotech
Segment. “This reinforces Lonza’s mission to support life-saving
medicines by being a reliable supplier of drug substance for our
customers with high-quality commercial GMP manufacturing services
delivered to the market.”
About Bristol-Myers Squibb
Bristol-Myers Squibb is a global biopharmaceutical company whose
mission is to discover, develop and deliver innovative medicines
that help patients prevail over serious diseases. For more
information, please visit www.bms.com or follow us on Twitter at
http://twitter.com/bmsnews.
About Lonza
Lonza is one of the world’s leading and most-trusted suppliers
to the pharmaceutical, biotech and specialty ingredients markets.
We harness science and technology to create products that support
safer and healthier living and that enhance the overall quality of
life.
Not only are we a custom manufacturer and developer, Lonza also
offers services and products ranging from active pharmaceutical
ingredients and stem-cell therapies to drinking water sanitizers,
from the vitamin B compounds and organic personal care ingredients
to agricultural products, and from industrial preservatives to
microbial control solutions that combat dangerous viruses, bacteria
and other pathogens.
Founded in 1897 in the Swiss Alps, Lonza today is a
well-respected global company with more than 40 major manufacturing
and R&D facilities and approximately 10,000 employees
worldwide. The company generated sales of about CHF 3.6 billion in
2013 and is organized into two market-focused segments: Pharma
& Biotech and Specialty Ingredients. Further information can be
found at www.lonza.com.
Photos/Multimedia Gallery Available:
http://www.businesswire.com/multimedia/home/20141030006207/en/
Bristol-Myers SquibbMedia:Laura Hortas, +1
609-252-4587laura.hortas@bms.comorFrederick Egenolf, +1
609-252-4875frederick.egenolf@bms.comorInvestors:Ranya
Dajani, +1 609-252-5330ranya.dajani@bms.comorRyan Asay, +1
609-252-5020ryan.asay@bms.comorLonzaMedia:Dominik
Werner, +41 61 316 8798dominik.werner@lonza.comorConstance Ward,
+41 61 316 8840constance.ward@lonza.comorColleen Floreck, +1 201
316 9290colleen.floreck@lonza.comorInvestors:Dirk Oehlers,
+41 61 316 8540dirk.oehlers@lonza.com
Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
From Sep 2024 to Oct 2024
Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
From Oct 2023 to Oct 2024